Player FM uygulamasıyla çevrimdışı Player FM !
Sarilumab and Polymyalgia Rheumatica
Manage episode 382345096 series 2931422
Polymyalgia rheumatica is a common rheumatic disorder. Steroids are the mainstay of therapy despite significant adverse reactions. Join host, Geoff Wall, as he evaluates a new treatment for PMR.
The GameChanger
Sarilumab is now FDA-approved for relapsing polymyalgia rheumatica. Sarilumab can be an alternative to long-term steroid therapy or methotrexate.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos GD, Marrache F, Patel N, Dasgupta B; SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023 Oct 5;389(14):1263-1272. doi: 10.1056/NEJMoa2303452. PMID: 37792612.
https://www.nejm.org/doi/full/10.1056/NEJMoa2303452
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the diagnosis and treatment of polymyalgia rheumatica
2. Assess the SAPHYR study and the role of sarilumab for treatment of polymyalgia rheumatica
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-352-H01-P
Initial release date: 11/6/2023
Expiration date: 11/6/2024
Additional CPE details can be found here.
Bölümler
1. Sarilumab and Polymyalgia Rheumatica (00:00:00)
2. New Medication for Polymyositromatica (PMR) Treatment (00:00:07)
3. Interleukin-6 Blockers in PMR Treatment (00:10:39)
4. Severellumab for PMR (00:18:55)
297 bölüm
Manage episode 382345096 series 2931422
Polymyalgia rheumatica is a common rheumatic disorder. Steroids are the mainstay of therapy despite significant adverse reactions. Join host, Geoff Wall, as he evaluates a new treatment for PMR.
The GameChanger
Sarilumab is now FDA-approved for relapsing polymyalgia rheumatica. Sarilumab can be an alternative to long-term steroid therapy or methotrexate.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos GD, Marrache F, Patel N, Dasgupta B; SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023 Oct 5;389(14):1263-1272. doi: 10.1056/NEJMoa2303452. PMID: 37792612.
https://www.nejm.org/doi/full/10.1056/NEJMoa2303452
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the diagnosis and treatment of polymyalgia rheumatica
2. Assess the SAPHYR study and the role of sarilumab for treatment of polymyalgia rheumatica
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-352-H01-P
Initial release date: 11/6/2023
Expiration date: 11/6/2024
Additional CPE details can be found here.
Bölümler
1. Sarilumab and Polymyalgia Rheumatica (00:00:00)
2. New Medication for Polymyositromatica (PMR) Treatment (00:00:07)
3. Interleukin-6 Blockers in PMR Treatment (00:10:39)
4. Severellumab for PMR (00:18:55)
297 bölüm
All episodes
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.